pralsetinib
blueprint medicines,roche
['nsclc', 'pralsetinib', 'lung', 'sclc', ' arrow']
#esmo22 | updated efficacy and safety data from the phase 1/2 arrow study of pralsetinib in patients (pts) with advanced ret fusion+ non-small cell lung cancer (nsclc) - #earlyphaseclinicaltrial by 
L’IUCT-Oncopole réunit l’expertise de l’Institut Claudius Regaud (Centre de lutte contre le #cancer) et des services de cancérologie du CHU de Toulouse.